KOSDAQBiotech & Pharma048410

Hyundai Bioscience

₩6,100▲ 2.18%2026-11-18 close
Market Cap
₩588.7B
Turnover
₩4.8B
Volume
780K
Shares out.
96.5M
PER
—
PBR
6.2×
EPS
-₩295
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses persist; clinical data is the key checkpoint

With a narrow sales base and continuing operating losses, the clinical progress of the antiviral candidate Jepty is the next checkpoint.

  1. 1

    Revenue fell 76.6% year on year to KRW 3.52 billion in 2025, and the company turned to an operating loss of KRW 18.2 billion.

  2. 2

    The net loss attributable to controlling shareholders continued for four consecutive years from 2022 to 2025, and total equity at year-end 2025 was KRW 110.7 billion.

  3. 3

    Third-quarter 2026 revenue was KRW 462 million, down 16.5% year on year, while the net loss attributable to controlling shareholders narrowed to KRW 6.84 billion from the prior quarter.

  4. 4

    Jepty is in an integrated dengue Phase 2/3 trial (DEN-201), which was formally presented at IDWeek 2026 in October 2026.

  5. 5

    Because the last four quarters were net losses, PER is not calculated, and the valuation discussion centers on a premium to book value.

02

Business structure

Hyundai Bioscience was spun off from Hyundai Electronics in 2000 and is a bio-pharmaceutical and cosmeceutical company; it largely exited its IT business in 2018 and reoriented around biotech.

Its production base is a plant in Gimcheon, Gyeongbuk, and it runs R&D and manufacturing and sales through overseas joint ventures and subsidiaries in Japan and the United States. Its display business has generated virtually no revenue since 2019, so the sales base has narrowed to bio hair-care products and cosmetics.

A 2026 review still describes overseas sales of bio hair-care and cosmetics products, including Vitabrid C12, as the base, while new-drug commercialization has been slow. The core new-drug candidate is Jepty (CP-COV03), an oral niclosamide-based compound that uses a drug-delivery technology.

In Vietnam, it is in a Phase 2/3 trial for dengue fever, while CP-PCA07 for prostate cancer in Korea is preparing to enroll patients for a Phase 1 study. In October 2026, an integrated dengue and related infectious disease Phase 2/3 trial, DEN-201, was formally presented at IDWeek 2026 in Washington, D.C.

Around the same period, a plan for a Phase 2 trial in severe fever with thrombocytopenia syndrome (SFTS) was reported, with patient recruitment cited as the key issue. Clinical trials, regulatory consultations and product approval are separate procedures.

The largest shareholder group, C&Pharm and four others, holds 11.40%. The competitive field overlaps with domestic and foreign companies developing antiviral candidates at the clinical stage, but its revenue depends on cosmetics and hair-care products, which differs from large bio companies with production-based sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩600M-₩4.6B−835.3%
2025Q4₩1.9B-₩4.4B−230.9%
2026Q1₩300M-₩4.7B−1436.9%
2026Q2₩500M-₩5.5B−1063.7%
2026Q3₩500M-₩5.2B−1119.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩7.9B-₩26.4B-₩15.8B−335.7%−27.1%15.6%
2023₩9.5B-₩9.8B-₩14.5B−103.2%−32.0%16.6%
2024₩15.1B₩800M-₩6.9B5.3%−17.6%71.7%
2025₩3.5B-₩18.2B-₩22.1B−516.3%−20.0%18.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

In the annual disclosed results, revenue rose from KRW 7.85 billion in 2022 to KRW 9.48 billion in 2023, a 20.8% increase, and then to KRW 15.1 billion in 2024, a 58.7% increase; 2024 was the largest year in the 2022 to 2025 period. Revenue fell 76.6% to KRW 3.52 billion in 2025, making it the smallest year.

The operating loss was KRW 26.4 billion in 2022 and KRW 9.79 billion in 2023, the company then posted an operating profit of KRW 791 million in 2024, and in 2025 it returned to an operating loss of KRW 18.2 billion.

The operating margin was -335.7% in 2022, -103.2% in 2023, 5.3% in 2024 and -516.3% in 2025, moving sharply with changes in the revenue base.

The net loss attributable to controlling shareholders was KRW 15.8 billion in 2022, KRW 14.5 billion in 2023, KRW 6.93 billion in 2024 and KRW 22.1 billion in 2025, a four-year run of losses. The net loss including non-controlling interests was disclosed at the same amounts for each year.

Operating cash flow was -KRW 16.5 billion in 2022, -KRW 6.01 billion in 2023, KRW 2.26 billion positive in 2024, and -KRW 17 billion in 2025, so apart from 2024 cash flowed out of operations. The debt ratio fell from 71.7% in 2024 to 18.1% in 2025.

Quarterly, revenue was KRW 1.92 billion in the fourth quarter of 2025, up 247.6% from the prior quarter, then KRW 325 million in the first quarter of 2026, down 83.1%, and KRW 462 million in the third quarter of 2026, down 16.5% year on year.

The operating loss ran for five consecutive quarters from KRW 4.62 billion in the third quarter of 2025 to KRW 5.17 billion in the third quarter of 2026, with the largest at KRW 5.54 billion in the second quarter of 2026.

The net loss attributable to controlling shareholders peaked at KRW 11.6 billion in the second quarter of 2026, and the third-quarter figure of KRW 6.84 billion narrowed from both the prior quarter and the year-earlier quarter.

The four-quarter total for the net loss attributable to controlling shareholders is KRW 28.5 billion. In the third quarter of 2026, the net loss narrowed, but the operating loss widened from the year-earlier quarter, so the operating-level deficit expanded.

05

Industry analysis

The antiviral and infectious disease treatment field targets conditions where standard therapies are limited. A professor at UC San Diego School of Medicine explained that dengue and other febrile viral diseases are hard to tell apart in their early symptoms, so early intervention with broad antivirals is needed.

For SFTS, the company's representative pointed to the absence of treatment alternatives, which supports the view that unmet need is large. In this field, clinical data and regulatory outcomes determine business value more than market size.

In terms of cycle position, the company is at an early development stage, with clinical-stage pipelines central to the business while commercial sales have shrunk.

Large bio-pharmaceutical peers with production-based sales can partly absorb clinical failure risk through product revenue, whereas Hyundai Bioscience has less revenue to absorb such risk.

Many domestic and foreign companies are developing candidates in infectious diseases, so trial design and the speed of patient enrollment are the differentiators. At IDWeek 2026, a leading antiviral researcher presented Jepty's integrated trial design and early data, which allowed external academic review.

On investor sentiment, one reading of recent trading is that a sharp rise and heavy volume show attention but do not settle the direction of earnings or fair value. In short, the company's clinical pace and regulatory discussions, more than industry conditions alone, determine its position in the sector.

06

Outlook

The most concrete schedule the company has disclosed is the integrated dengue Phase 2/3 trial of Jepty (DEN-201). The company plans to decide the Phase 3 dose based on dose-specific safety and efficacy data from Phase 2.

The Phase 2 data readout is therefore the largest next checkpoint, and its timing has not been disclosed. For SFTS, a plan for a Phase 2 trial has been reported, with patient recruitment identified as the key issue. CP-PCA07, a prostate cancer candidate, is preparing for patient enrollment in a Phase 1 study.

On regulation, clinical trials, regulatory consultations and product approval are separate procedures, so trial results do not translate directly into an approval timetable. On the business side, the overseas sales base for hair-care and cosmetics products remains as the existing revenue.

On reported results, the next regular checkpoint is the 2026 annual report, which will fix annual revenue, operating profit and loss, and the net loss attributable to controlling shareholders.

Fourth-quarter results are included in the annual report rather than a separate quarterly filing, so they are confirmed with the annual figures. At an external academic presentation, an outside expert presented Jepty's integrated trial design directly, which allowed independent review.

On funding, share capital rose to KRW 48.0 billion at year-end 2025, indicating external capital was raised, and any further financing can be tracked through future filings. Overall, clinical timelines and the figures in the regular reports will be the reference points for future checks.

07

Valuation

PER
—
PBR
6.2×
ROE
-27.5%
EPS
-₩295
BPS
₩1,001
Dividend per share
₩0

Because the last four quarters were net losses, PER is not calculated, so a comparison on an earnings basis does not hold. On an asset basis, the price-to-book ratio sits in a range with a large premium over net asset value.

Total equity at year-end 2025 was KRW 110.7 billion, and share capital rose from KRW 19.9 billion at year-end 2024 to KRW 48.0 billion at year-end 2025, so the capital base expanded.

Over several years, the operating result turned from profit in 2024 to a loss in 2025, so a sustained earnings recovery has not yet been confirmed. No dividend income currently accrues, so a shareholder-return comparison based on dividends is difficult.

For a company without an earnings base, peer comparisons usually rely on asset-based measures and pipeline value. A large premium over net assets may reflect market expectations for the pipeline, but the clinical data supporting those expectations is still at an early stage.

Valuation figures move with the share price, so the starting point for interpretation is whether earnings and clinical progress change together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Expanding pipeline indications

The integrated dengue and related infectious disease Phase 2/3 trial, DEN-201, was formally presented in October 2026. A Phase 2 plan for an SFTS treatment was reported in the same period.

The Phase 1 enrollment for the prostate cancer candidate CP-PCA07 is also in preparation, so the target diseases span several areas.

Capital base and low debt

Total equity at year-end 2025 was KRW 110.7 billion, and total liabilities were KRW 20 billion. Share capital rising from KRW 19.9 billion to KRW 48.0 billion also reflects an expanded capital base from external funding.

Narrowing losses and a past profit year

The net loss attributable to controlling shareholders narrowed from KRW 11.6 billion in the second quarter of 2026 to KRW 6.84 billion in the third quarter, and it also narrowed year on year. The company posted an operating profit of KRW 791 million in 2024, so a profitable year has occurred in its history.

09

Bear factors

Thin revenue base

Revenue in 2025 was KRW 3.52 billion, down 76.6% from the prior year. The sales base remains overseas sales of hair-care and cosmetics products, and new-drug commercialization has been slow. Third-quarter 2026 revenue of KRW 462 million fell 16.5% year on year.

Continued losses and cash outflow

Operating cash flow in 2025 was -KRW 17 billion. The four-quarter total of the net loss attributable to controlling shareholders is KRW 28.5 billion, and the operating loss has been in deficit for five consecutive quarters from the third quarter of 2025 to the third quarter of 2026. The operating-level loss widened from the year-earlier quarter even in the third quarter of 2026.

Clinical and approval uncertainty

The Phase 3 dose will be set based on dose-specific data from Phase 2. Even if development succeeds, several steps remain before it becomes commercial revenue.

10

Risk factors

Clinical and regulatory risk

The integrated dengue trial of Jepty is in Phase 2/3, and the Phase 3 dose will depend on Phase 2 data. If clinical results fall short of expectations, the development timeline could be delayed. Regulatory consultations and product approval are separate procedures, adding further timing variables.

Funding risk

Operating cash flow in 2025 was -KRW 17 billion, and the four-quarter net loss attributable to controlling shareholders totals KRW 28.5 billion. Share capital rising to KRW 48.0 billion at year-end 2025 means external funding was raised. If further funds are needed, possible dilution of existing shareholders is also an item to watch.

Governance and related-party risk

The largest shareholder group, C&Pharm and four others, holds 11.40%. Media reports said that as of the third quarter of 2024, most receivables carried allowances, and the full amount invested in a US joint sales company was written off as an impairment. Terms and recoverability of related-party transactions remain items to monitor.

11

What to watch next

  1. Around late March 2027 (annual report filing deadline)

    This is where annual 2026 revenue, operating profit and loss, and the net loss attributable to controlling shareholders are confirmed in the regular report. Fourth-quarter results are included, so this is the point to reconcile with the first-to-third-quarter filings.

  2. Timing not disclosed

    The dose-specific safety and efficacy data from the Jepty dengue Phase 2/3 trial (DEN-201). These data underpin the Phase 3 dose decision and are the core point for judging clinical progress.

  3. Timing not disclosed (patient enrollment start not announced)

    Whether patient enrollment begins for the SFTS treatment Phase 2 trial. Recruitment was cited as the key issue, so the timing and pace of enrollment will signal whether the schedule is slipping.

  4. Timing not disclosed (enrollment start not announced)

    The start of patient enrollment for the CP-PCA07 prostate cancer Phase 1 trial. Data accumulate only after enrollment starts, so this is where the pipeline expansion can be confirmed in practice.

  5. Ad hoc disclosures (timing undetermined)

    Funding disclosures such as rights offerings, and disclosures on transactions with the largest shareholder and affiliates. This is where changes in share capital and related-party structure can be checked.

12

Overall view

Hyundai Bioscience saw revenue fall to KRW 3.52 billion in 2025 and turned to an operating loss of KRW 18.2 billion, and the discussion centers on whether Jepty's clinical progress continues.

On the disclosed results, the net loss attributable to controlling shareholders continued for four consecutive years from 2022 to 2025, and the four-quarter total is KRW 28.5 billion.

The financial structure, with total equity of KRW 110.7 billion and total liabilities of KRW 20 billion at year-end 2025, shows a relatively low debt burden, but operating cash flow was -KRW 17 billion in 2025.

Positive factors include the integrated dengue Phase 2/3 trial of Jepty, the planned SFTS Phase 2 trial, and preparation for the CP-PCA07 Phase 1 study. Negative factors include a sales base limited to hair-care and cosmetics products, with third-quarter 2026 revenue down 16.5% year on year.

On governance, the 11.40% stake held by the largest shareholder group and the history of impairments on affiliate receivables remain items to monitor. The next checkpoints are the Jepty Phase 2 data and the Phase 3 dose decision, along with the 2026 annual report.

This material is provided for information only and does not contain an opinion that serves as a basis for investment decisions.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. bosoop.com
  3. comp.fnguide.com
  4. greened.kr
  5. markets.hankyung.com
  6. kormedi.com
  7. investing.com
  8. cosinkorea.com
  9. jasoseol.com
  10. jobkorea.co.kr
  11. joongangenews.com
  12. job-post.co.kr
  13. anewsa.com
  14. anewsa.com
  15. anewsa.com
  16. job-post.co.kr
  17. anewsa.com
  18. cbci.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis